Table 1.
Baseline criteria
| Cases (11) | Controls (33) | |||
|---|---|---|---|---|
| Number | Percentage | Number | Percentage | |
| Sex | ||||
| Women | 5 | 46 | 11 | 33 |
| Men | 6 | 54 | 22 | 67 |
| Age in years | ||||
| Median, range, IQR | 48, 25–57, 43–50 | 43, 18–57, 27–50 | ||
| Histological and molecular tumour type | ||||
| Diffuse astrocytoma IDH mt, 1p/19q intact | 6 | 55 | 23 | 70 |
| Oligodendroglioma IDH mt, 1p/19q codeleted | 1 | 9 | 3 | 9 |
| Glioma IDH wt | 2 | 18 | 3 | 9 |
| Glioma not otherwise specified | 2 | 18 | 4 | 12 |
| Treatment before ASL-MRI | ||||
| No treatment | 2 | 18 | 11 | 33 |
| Temozolomide | 2 | 18 | 1 | 3 |
| Radiotherapy | 2 | 18 | 7 | 21 |
| Radiotherapy and temozolomide | 5 | 46 | 13 | 39 |
| Radiotherapy and PCV | 0 | 0 | 1 | 3 |
| Time from ASL-MRI to MP in days | ||||
| Median, range, IQR | 100, 17–203, 31–135 | |||
| Time from first surgery to MP in months | ||||
| Median, range, IQR | 37, 3–116, 17–44 | |||
| Seizures preceding ASL: Yes | 4 | 6 | ||
| Time between last seizure and ASL in days | ||||
| Median, range, IQR | 21, 1–75, 4–64 | 26, 14–79, 19–63 | ||
IQR, interquartile range; IDH wt, IDH wildtype; IDH mt, IDH-mutated; PCV, procarbazine/lomustine/vincristine; MP, malignant progression; ASL, arterial spin labeling MRIs